ELI LILLY & Co (LLY)
Pharmaceutical Preparations · Pharmaceutical Preparations · NYSE
$1,280.34
+4.46%
Investingg Score
73.5 / 100
Buy
Business overview
- Gross margin stands at 83 percent.
- Operating margin and free cash flow margin are data unavailable.
These figures show strong production profitability, though the lack of operating and cash flow margins introduces some uncertainty regarding overall expense control.
Financial health
- Market capitalization is reported as 0.
- Balance sheet score is 34 out of 100.
These metrics indicate a low balance sheet score alongside an unpopulated market cap figure, highlighting limited available visibility into overall financial positioning.
- Gross Margin
- 83.0%
- Operating Margin
- Data unavailable
- Current Ratio
- 1.6x
- Debt / Equity
- 1.54
- Free Cash Flow (TTM)
- Data unavailable
- Interest Coverage
- Data unavailable
Valuation
- Forward P/E ratio is 28.48.
- P/E, EV to EBITDA, P/S ratio, and free cash flow yield are either unavailable or listed as 0.
These data points suggest a moderate forward pricing multiple, while the absence of trailing P/S and other standard ratios leaves valuation interpretation incomplete.
- P/E (TTM)
- Data unavailable
- Forward P/E
- 28.5x
- Price / Sales
- 0.0x
- EV / EBITDA
- Data unavailable
- FCF Yield
- Data unavailable
Key risks
- Certain key valuation and operating margin metrics are unavailable, limiting full visibility.
- The balance sheet score is relatively low at 34.
- The RSI of 68.97 approaches overbought territory, creating potential short-term volatility.
Market cap $0 · data as of 2026-08-19
Related stocks
Get the full interactive report
Technicals, earnings history, news, bull/base/bear scenarios, Ask the Stock, and more — free to start.
Analyze LLY with Investingg AINot investment advice. Investingg AI summarizes public data and AI-generated analysis for informational purposes only.